Medication info
Piozole Tablet (Pioglitazone Hydrochloride)

Piozole Tablet (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Austin Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, convex cylindrical tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200704286 · Notified 2007.04.12 · Insurance code 654303200

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medicine is administered orally once daily, regardless of meals. Treatment should be continued for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin, provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose, the dose of this medicine may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The patient's current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment in General Precautions). Treatment with this medicine should not be initiated if, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on use of this medicine in combination with other thiazolidinediones.
Child dose
Use is not recommended in children under 18 years of age because there is no experience with its use.

Ingredients

Manufacturer
Austin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control disorders in patients with Type 2 diabetes
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with Type 2 diabetes. It can be used alone, but in cases where blood sugar control is inadequate with other hypoglycemic agents, it is administered in combination with sulfonylurea, metformin, or insulin. For patients with Type 2 diabetes, nutritional counseling, weight loss, and exercise therapy are essential, which are very important not only for initial treatment but also for maintaining the effectiveness of medication. Therefore, this medication is effectively used to improve blood sugar control.

How to take

Adult dose

This medicine is administered orally once daily, regardless of meals. Treatment should be continued for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin, provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose, the dose of this medicine may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The patient's current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment in General Precautions). Treatment with this medicine should not be initiated if, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on use of this medicine in combination with other thiazolidinediones.

Child dose

Use is not recommended in children under 18 years of age because there is no experience with its use.

Precautions

This medication aids blood sugar control in Type 2 diabetes patients and works by improving insulin resistance. When taking this medication, there is a risk of heart failure occurring or worsening in patients with compromised heart function, so symptoms such as changes in weight, shortness of breath, and swelling should be carefully monitored after treatment initiation. Patients with heart failure or a history of heart failure should not take this medication, and careful administration is necessary for patients with existing heart disease or a high risk of heart failure. This medication can cause fluid retention, leading to swelling, which may exacerbate heart failure symptoms, so immediate consultation with medical personnel is advised if symptoms occur. Additionally, patients with a history of bladder cancer or current active bladder cancer should not take this medication. If symptoms such as urinary disturbances or hematuria occur, inform a physician immediately. Patients with poor liver function or severe kidney impairment should also use this medication with caution, and liver enzyme levels should be monitored regularly. This medication carries a risk of hypoglycemia, so caution is necessary when taken with insulin or other hypoglycemic agents, and dosage adjustments of the concomitant medication may be required if hypoglycemic symptoms occur. In premenopausal women, this medication may promote ovulation, increasing the likelihood of pregnancy, so it is important to use appropriate contraceptive methods. Elderly patients or those in poor nutritional status, as well as those engaging in vigorous exercise, are also at risk of hypoglycemia and should use caution when taking this medication. During treatment, regular blood sugar and liver function tests should be conducted, and any abnormal symptoms should be reported to medical personnel immediately. Overdose may not produce specific symptoms, but tailored treatment may be necessary based on symptoms, so caution is needed. Finally, the safety and efficacy of this medication have not been established for children and it is not recommended for use in this age group.

Side effects

  • Congestive heart failure
  • excessive and rapid weight changes
  • shortness of breath
  • edema
  • fluid retention
  • inadequate blood sugar control
  • upper respiratory infection
  • headache
  • sinusitis
  • myalgia
Show 67 more
  • pharyngitis
  • edema
  • abdominal distension
  • weight gain
  • hypoglycemia
  • urinary tract infection
  • low back pain
  • dizziness
  • diarrhea
  • elevated serum creatine kinase
  • hypertension
  • heart failure
  • limb pain
  • chest pain
  • cardiovascular-related mortality
  • worsening of congestive heart failure
  • progression of congestive heart failure
  • visible hematuria
  • urinary disturbances
  • urgency
  • liver failure
  • vision loss
  • diabetic macular edema
  • liver damage
  • elevated serum ALT levels
  • elevated serum bilirubin levels
  • decreased hemoglobin
  • decreased hematocrit
  • elevated serum creatine kinase
  • fractures
  • dizziness
  • loss of appetite
  • constipation
  • upper abdominal pain
  • chest pain
  • fatigue
  • weakness
  • dyspepsia
  • nausea
  • cough
  • itching
  • trembling
  • chest discomfort
  • gastrointestinal disease
  • abdominal pain
  • epigastric discomfort
  • numbness
  • muscle rigidity
  • head discomfort
  • worsening of liver disease
  • urticaria
  • eczema
  • arthralgia
  • knee abnormalities
  • upper arm weakness
  • proteinuria
  • increased serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simple herpes
  • blurred vision
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that can prevent air and moisture exposure. It should be kept in a cool, dry place away from direct sunlight, ideally at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

White to grayish-white, convex cylindrical tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.